Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06974786 · ClinicalTrials.gov registry record · Phase 2
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
A Phase 2 study of Multiple Myeloma (MM) and Multiple Myeloma, Newly Diagnosed, sponsored by SCRI Development Innovations.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 9
- Study locations
NCT06974786: Recruiting Phase 2 study of Multiple Myeloma (MM) and Multiple Myeloma, Newly Diagnosed, sponsored by SCRI Development Innovations.
NCT06974786 is a Phase 2 study of Multiple Myeloma (MM) and Multiple Myeloma, Newly Diagnosed that is actively recruiting participants, run by SCRI Development Innovations. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06974786, a Phase 2 study of Multiple Myeloma (MM) and Multiple Myeloma, Newly Diagnosed, is actively recruiting participants, sponsored by SCRI Development Innovations.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidomide and daratumumab treatment (Arm B).
Primary Outcome
Rate of participants with MRD negativity (defined as \<10-5) after completion of the Maintenance 1 portion of the study.
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Elranatamab
- DRUG Daratumumab
- PROCEDURE autologous stem cell transplantation
Study Locations (9)
Wisconsin
- University of Wisconsin Clinical Science Center - Madison
- Medical College of Wisconsin - Milwaukee
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Colorado Blood Cancer Institute - Denver
Iowa
- University of Iowa - Iowa City
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Oncology Hematology Care - Cincinnati
Tennessee
- SCRI Oncology Partners - Nashville
Virginia
- Virginia Oncology Associates - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-08-08 |
| Est. Completion | 2033-04 |
| Phase | Phase 2 |
What NCT06974786 shows while recruiting
NCT06974786 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with Multiple Myeloma (MM) appearing as the primary indexed condition, and to 4 interventions - of which Lenalidomide is the first listed.
NCT06974786 lists 9 locations in 8 states (Wisconsin, Alabama, Colorado).
Frequently Asked Questions
What is clinical trial NCT06974786 about?
NCT06974786 is a clinical study titled "Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma". This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease ...
What is the current status of trial NCT06974786?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-08-08. Estimated completion is 2033-04.
What conditions does trial NCT06974786 study?
This clinical trial studies the following conditions: Multiple Myeloma (MM), Multiple Myeloma, Newly Diagnosed.
What interventions are being tested in trial NCT06974786?
The interventions under investigation include: Lenalidomide (DRUG), Elranatamab (DRUG), Daratumumab (DRUG), autologous stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT06974786?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06974786 being conducted?
This trial has 9 study locations across Alabama, Colorado, Iowa, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma (MM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06974786's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,264 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI